Related Experiment Video

Updated: May 6, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

17.7K

Harnessing dendritic cells for tumor antigen presentation

Stefan Nierkens1, Edith M Janssen

  • 1Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Geert Grooteplein 28, Nijmegen 6525 GA, The Netherlands. edith.janssen@cchmc.org.

Cancers
|November 12, 2013
PubMed

Insights

Harnessing dendritic cells (DCs) for cancer therapy shows promise. This review examines challenges in loading DCs with tumor antigens, a key step for effective anti-tumor T cell responses.

Area of Science:

  • Immunology
  • Cancer Therapy
  • Cellular Biology

Background:

  • Dendritic cells (DCs) are critical antigen-presenting cells for initiating anti-tumor T cell immunity.
  • Therapeutic strategies utilizing DCs for cancer treatment are under active investigation.
  • Current ex vivo DC-based therapies face challenges in clinical efficacy and logistical complexity.

Purpose of the Study:

  • This review critically analyzes obstacles in current dendritic cell-based cancer immunotherapies.
  • It specifically addresses the pivotal step of in vitro tumor antigen loading onto DCs.
  • The focus is on improving the priming of tumor-specific CD8+ and CD4+ T cells.

Main Methods:

  • This is a review article, synthesizing existing research on dendritic cell biology and cancer immunotherapy.
  • It examines literature pertaining to antigen loading techniques for ex vivo-generated DCs.
  • The review focuses on the in vitro aspects of DC manipulation for therapeutic purposes.

Main Results:

  • While ex vivo-generated and tumor-antigen loaded DCs are feasible, significant hurdles remain.
  • The efficiency and effectiveness of in vitro DC antigen loading directly impact T cell priming.
  • Overcoming these obstacles is essential for enhancing clinical trial success rates.

Conclusions:

  • Improving the in vitro loading of dendritic cells with tumor antigens is crucial for advancing DC-based cancer immunotherapy.
  • Addressing current challenges can lead to more effective and cost-efficient cell therapies.
  • Further research into optimal antigen loading methods will enhance anti-tumor T cell responses.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.9K
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

3.0K

Related Concept Videos

Antigen Presenting Cells01:22

Antigen Presenting Cells

The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
13.7K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.8K
Antigen Processing Pathways01:31

Antigen Processing Pathways

MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
2.9K